Glaxo Says It Will Stop Paying Doctors to Promote Drugs – New York Times

Related Posts:

Doctors Say Heart Drug Raised Risk of an Attack – New York November 20, 2013 By ANDREW POLLACK Cardiologists who reported on a clinical trial said the company making the drug failed to turn over data that showed it didn’t work. Published: November 20, 2013 at 5:00AM Source: NYT Business Day http://www.nytimes.com/2013/11/20/business/doctors-say-heart-drug-raised-risk-of-an-attack.html Drugs (Pharmaceuticals), Clinical Trials, Heart

Questions for a New Class of Cholesterol Drugs – New York… November 15, 2013 By KATIE THOMAS A promising new class of cholesterol-lowering drugs known as PCSK9 inhibitors are being developed. Published: November 15, 2013 at 5:00AM Source: NYT Business Day http://www.nytimes.com/2013/11/15/business/questions-for-a-new-class-of-cholesterol-drugs.html Medicine and Health, Research, Cholesterol, Drugs (Pharmaceuticals), Generic Brands and Products

F.D.A. Lifts Some Restrictions on Avandia – New York Times November 26, 2013 By SABRINA TAVERNISE Doctors said the move was unlikely to breathe new life into the diabetes drug, which has been largely discredited in the United States. Published: November 26, 2013 at 5:00AM Source: NYT Business Day http://www.nytimes.com/2013/11/26/business/fda-lifts-some-restrictions-on-avandia.html Drugs (Pharmaceuticals), Avandia (Drug), Diabetes

F.D.A. Proposes Letting Generic Drug Companies Alter Labels… November 8, 2013 [flickr_feed template="default" count=1 text="business"] By KATIE THOMAS The Food and Drug Administration’s move, if approved, would make generic firms equal to brand-name drug makers and open both to lawsuits by patients. Published: November 9, 2013 at 5:00AM Source: NYT Business Day http://www.nytimes.com/2013/11/09/business/fda-proposes-letting-generic-drug-companies-alter-labels.html Generic Brands and Products, Drugs (Pharmaceuticals), Labeling and Labels, Regulation and Deregulation of Industry

Pressure From Generic Drugs Shrinks Profit at Pfizer – October 29, 2013 [flickr_feed template="default" count=1 text="business"] By THE ASSOCIATED PRESS The pharmaceutical giant reported net income in the third quarter fell 19 percent to $2.59 billion, or 39 cents a share. Published: October 30, 2013 at 4:00AM Source: NYT Business Day http://www.nytimes.com/2013/10/30/business/pressure-from-generic-drugs-shrinks-profit-at-pfizer.html Company Reports, Drugs (Pharmaceuticals)